Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

USA - NASDAQ:SCYX - US8112922005 - Common Stock

0.77 USD
0 (0%)
Last: 10/24/2025, 8:00:02 PM
0.769 USD
0 (-0.13%)
After Hours: 10/24/2025, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, SCYX scores 4 out of 10 in our fundamental rating. SCYX was compared to 192 industry peers in the Pharmaceuticals industry. SCYX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SCYX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SCYX has reported negative net income.
In the past year SCYX has reported a negative cash flow from operations.
In the past 5 years SCYX reported 4 times negative net income.
In the past 5 years SCYX reported 4 times negative operating cash flow.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of SCYX (-32.16%) is comparable to the rest of the industry.
With a Return On Equity value of -43.89%, SCYX perfoms like the industry average, outperforming 56.25% of the companies in the same industry.
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROIC N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

With an excellent Gross Margin value of 114.98%, SCYX belongs to the best of the industry, outperforming 99.48% of the companies in the same industry.
SCYX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for SCYX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 114.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

6

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCYX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SCYX has more shares outstanding
Compared to 1 year ago, SCYX has a worse debt to assets ratio.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -8.81, we must say that SCYX is in the distress zone and has some risk of bankruptcy.
SCYX has a Altman-Z score of -8.81. This is in the lower half of the industry: SCYX underperforms 65.63% of its industry peers.
SCYX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.81
ROIC/WACCN/A
WACC8.77%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 5.20 indicates that SCYX has no problem at all paying its short term obligations.
The Current ratio of SCYX (5.20) is better than 70.31% of its industry peers.
SCYX has a Quick Ratio of 5.20. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SCYX (5.20) is better than 70.31% of its industry peers.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

SCYX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.44%, which is quite impressive.
SCYX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -66.43%.
SCYX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 99.01% yearly.
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%

3.2 Future

SCYX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.31% yearly.
The Revenue is expected to grow by 25.23% on average over the next years. This is a very strong growth
EPS Next Y-46.05%
EPS Next 2Y57.7%
EPS Next 3Y23.68%
EPS Next 5Y15.31%
Revenue Next Year-65.93%
Revenue Next 2Y87.7%
Revenue Next 3Y56%
Revenue Next 5Y25.23%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 3.59, which indicates a rather cheap valuation of SCYX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SCYX indicates a rather cheap valuation: SCYX is cheaper than 98.96% of the companies listed in the same industry.
SCYX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.99.
Industry RankSector Rank
PE N/A
Fwd PE 3.59
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as SCYX's earnings are expected to grow with 23.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.7%
EPS Next 3Y23.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCYX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (10/24/2025, 8:00:02 PM)

After market: 0.769 0 (-0.13%)

0.77

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners26.58%
Inst Owner Change0.13%
Ins Owners2.09%
Ins Owner Change3.02%
Market Cap32.28M
Revenue(TTM)3.26M
Net Income(TTM)-19517000
Analysts84.44
Price Target4.76 (518.18%)
Short Float %2.34%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.07%
Min EPS beat(2)27.76%
Max EPS beat(2)38.38%
EPS beat(4)4
Avg EPS beat(4)36.63%
Min EPS beat(4)20.51%
Max EPS beat(4)59.89%
EPS beat(8)6
Avg EPS beat(8)23.48%
EPS beat(12)8
Avg EPS beat(12)7.4%
EPS beat(16)11
Avg EPS beat(16)17.41%
Revenue beat(2)2
Avg Revenue beat(2)395.48%
Min Revenue beat(2)22.61%
Max Revenue beat(2)768.35%
Revenue beat(4)2
Avg Revenue beat(4)152.71%
Min Revenue beat(4)-90.6%
Max Revenue beat(4)768.35%
Revenue beat(8)5
Avg Revenue beat(8)170.56%
Revenue beat(12)8
Avg Revenue beat(12)116.76%
Revenue beat(16)9
Avg Revenue beat(16)82.59%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-44.45%
EPS NQ rev (3m)-44.45%
EPS NY rev (1m)3.08%
EPS NY rev (3m)-137.74%
Revenue NQ rev (1m)-94.44%
Revenue NQ rev (3m)-94.44%
Revenue NY rev (1m)-76.99%
Revenue NY rev (3m)-76.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 3.59
P/S 9.91
P/FCF N/A
P/OCF N/A
P/B 0.73
P/tB 0.73
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)0.21
Fwd EY27.82%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.08
BVpS1.06
TBVpS1.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.16%
ROE -43.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 114.98%
FCFM N/A
ROA(3y)-14.27%
ROA(5y)-24.82%
ROE(3y)-636.53%
ROE(5y)-446.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z -8.81
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.33%
EPS Next Y-46.05%
EPS Next 2Y57.7%
EPS Next 3Y23.68%
EPS Next 5Y15.31%
Revenue 1Y (TTM)-66.43%
Revenue growth 3Y-34.22%
Revenue growth 5Y99.01%
Sales Q2Q%85.33%
Revenue Next Year-65.93%
Revenue Next 2Y87.7%
Revenue Next 3Y56%
Revenue Next 5Y25.23%
EBIT growth 1Y29.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-336.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-336.99%
OCF growth 3YN/A
OCF growth 5YN/A

SCYNEXIS INC / SCYX FAQ

Can you provide the ChartMill fundamental rating for SCYNEXIS INC?

ChartMill assigns a fundamental rating of 4 / 10 to SCYX.


What is the valuation status of SCYNEXIS INC (SCYX) stock?

ChartMill assigns a valuation rating of 3 / 10 to SCYNEXIS INC (SCYX). This can be considered as Overvalued.


What is the profitability of SCYX stock?

SCYNEXIS INC (SCYX) has a profitability rating of 2 / 10.


What is the financial health of SCYNEXIS INC (SCYX) stock?

The financial health rating of SCYNEXIS INC (SCYX) is 6 / 10.